A mass spectrometric insight into the origins of benign gynecological disorders

Huiliang Yang, Lau WB, Wayne Bond Lau, Bonnie Lau, Lau B, Xuan Yu, Xuan Y, Yu Xuan, Shengtao Zhou, Linjie Zhao, Zhao L, Luo Z, Zhongyue Luo, Lin Q, Qiao Lin, Ren N, Ning Ren, Xia Zhao, Zhao X, Yuquan Wei, Wei Y
Mass spectrometry reviews · 2015 · vol. 36(3) , pp. 450–470 · doi:10.1002/mas.21484 · PMID:26633258 · W2184313016
Review OA: closed CC0 ⤵ 31 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Mass spectrometry was used to analyze molecular alterations in benign gynecological disorders, identifying novel protein and metabolite biomarkers for improved diagnosis and management.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Applications of mass spectrometry (MS) are rapidly expanding and encompass molecular and cellular biology. MS aids in the analysis of in vivo global molecular alterations, identifying potential biomarkers which may improve diagnosis and treatment of various pathologies. MS has added new dimensionality to medical research. Pioneering gynecologists now study molecular mechanisms underlying female reproductive pathology with MS-based tools. Although benign gynecologic disorders including endometriosis, adenomyosis, leiomyoma, and polycystic ovarian syndrome (PCOS) carry low mortality rates, they cause significant physical, mental, and social detriments. Additionally, some benign disorders are unfortunately associated with malignancies. MS-based technology can detect malignant changes in formerly benign proteomes and metabolomes with distinct advantages of speed, sensitivity, and specificity. We present the use of MS in proteomics and metabolomics, and summarize the current understanding of the molecular pathways concerning female reproductive anatomy. Highlight discoveries of novel protein and metabolite biomarkers via MS-based technology, we underscore the clinical application of these techniques in the diagnosis and management of benign gynecological disorders. © 2015 Wiley Periodicals, Inc. Mass Spec Rev 36:450-470, 2017.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Genital Diseases, Female Mass Spectrometry Metabolomics Proteomics Adenomyosis Adenomyosis Adenomyosis Adenomyosis Animals Animals Biomarkers Biomarkers Biomarkers Biomarkers Endometriosis Endometriosis Endometriosis Endometriosis Female Female

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (100)

Cited by (31)

Source provenance

europepmc
last seen: 2026-10-12T06:17:10.165071+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:16:50.396854+00:00
License: CC0 · commercial use OK